BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31571848)

  • 1. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
    Bogart M; Stanford RH; Laliberté F; Germain G; Wu JW; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():343-352. PubMed ID: 30863037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
    Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
    Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
    Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
    Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice.
    Sansbury LB; Bains C; Lipson DA; Ismaila AS; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1255-1264. PubMed ID: 33986594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.